CU 101
Alternative Names: CU-101Latest Information Update: 10 Aug 2022
Price :
$50 *
At a glance
- Originator CURACLE
- Class Anti-ischaemics; Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Myocardial infarction
Most Recent Events
- 10 Aug 2022 Pharmacodynamics data from a preclinical trial in myocardial infarcion released by CURACLE (CURACLE pipeline, August 2022)
- 30 Jun 2022 Phase-I clinical trials in Myocardial infarction in USA (PO) before June 2022 (CURACLE pipeline, August 2022)
- 30 Jun 2022 CURACLE completes a phase I trial in Myocardial infarction in USA (PO) (CURACLE pipeline, August 2022)